Blue Trust Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Blue Trust Inc’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24	Closed	-$642	–	2938
2024 Q3	$642	Buy	+24	New	+$749	﹤0.01%	2766

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Blue Trust Inc's SUPN Position: Q4 2024 in Review

Blue Trust Inc sold out of Supernus Pharmaceuticals (SUPN) in Q4 2024, closing a stake of 24 shares — an estimated $642 sold.

Blue Trust Inc first reported a position in SUPN in Q3 2024 and held it in 1 quarter. The position peaked at $642 in Q3 2024. 294 funds tracked by Wall St. Rank hold SUPN as of Q4 2024.

Blue Trust Inc reported no remaining Supernus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Blue Trust Inc sold 24 Supernus Pharmaceuticals shares in Q4 2024, an estimated $642.
Blue Trust Inc first reported a position in Supernus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Blue Trust Inc's Supernus Pharmaceuticals position peaked at $642 in Q3 2024.
294 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.